A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.
After a bone marrow transplant, elevated blood levels of REG3-alpha protein, shown here in brown, are an indicator of intestinal graft-versus-host disease, a U-M study found.
Known as a hematopoietic stem cell transplant, these patients receive bone marrow or peripheral blood stem cells from a matched donor who is either a family member or an unrelated volunteer.
The most common fatal complication of this type of transplant is graft-versus-host disease (GVHD), where the newly transplanted immune system of the donor attacks the patient’s skin and internal organs. Up to 30 percent of recipients develop GVHD in their gastrointestinal tract, which is the organ most resistant to treatment.
Without invasive tests such as biopsies, however, GVHD can be difficult to distinguish from other causes of gastrointestinal distress, such as infection or side effects from medication.
The U-M team tested blood samples from over 1,000 patients who were treated in Ann Arbor, Germany and Japan.
“We believe we’ve found a reliable biomarker in the patients’ blood that is specific to graft-versus-host disease and therefore can help us to rapidly identify patients for whom standard treatment is likely to be insufficient,” says James L.M. Ferrara, M.D., co-lead author of the study and director of the U-M Combined Blood and Marrow Transplant Program. “This marker can also tell us whether a patient is likely to respond to therapy and may lead to an entirely new risk assessment for the disease. The findings were recently published online ahead of print publication in the journal Blood.
The marker, known as regenerating islet-derived 3-alpha (REG3-alpha), doesn’t prevent patients from still needing a biopsy, Ferrara cautions, but taken with other predictive indicators, it could help doctors to ensure patients get the most appropriate treatment as early as possible.
Doctors at U-M hope to start using the test clinically in early 2012.
Funding: The research was supported by grants from the National Institutes of Health, Hartwell Foundation and Doris Duke Charitable Foundation.
Disclosure: The authors report no potential conflicts of interest. The University is presently looking for licensing partners to help bring the technology to market.
Additional U-M authors: Andrew C. Harris, M.D.; Joel K. Greenson, M.D.; Thomas M. Braun, Ph.D.; John E. Levine, M.D.; Sung W.J. Choi, M.D.; Mark Vander Lugt, M.D.; Pavan Reddy, M.D.; Sophie Paczesny, M.D.
For a full list of authors and to read the abstract of the paper, “Regenerating islet-derived 3 alpha is a biomarker of gastrointestinal graft-versus-host disease,” visit: http://bit.ly/mR9daf
About the U-M Comprehensive Cancer Center:
The U-M Comprehensive Cancer Center is one of only 40 U.S. centers to earn the National Cancer Institute’s “Comprehensive” designation by meeting strict guidelines for: Extensive, interactive and innovative clinical and laboratory research; participation in NCI testing of new therapies; significant cancer prevention and control research; provision of patient education, community service and outreach as well as training for health professionals.
The Cancer Center is also a founding member of the National Comprehensive Cancer Network, a consortium of 21 premiere cancer centers formed to develop national guidelines to ensure consistent, high-quality and cost-effective cancer care.
U-M Cancer AnswerLine, 800-865-1125
Clinical trials at U-M, www.UMClinicalStudies.org
Web: www.UofMHealth.org | www.mcancer.org
Media Contacts Ian Demsky: firstname.lastname@example.org 734-764-2220